Regular follow-up to assess benefits versus harms helps guide continued therapy and safe discontinuation when necessary appropriately
These drugs are powerful stuff: If youre experiencing a reaction that you cant explain, please reach out to your healthcare provider
Compliance News | November 11, 2025 The administration, together with pharmaceutical manufacturers Eli Lilly and Novo Nordisk, announced an agreement to lower prices and expand access to glucagon-like peptide-1 receptor agonists (GLP-1s) for weight loss for those in the Medicare Part D and Medicaid programs as well as direct-to-consumer (DTC) purchasing
Polycystic Ovary Syndrome (PCOS) : PCOS is a common condition in women with insulin resistance and type 2 diabetes
However, they work best as part of a broader approach that includes regular exercise, balanced nutrition, quality sleep, and stress management.
This suggests that GLP-1 improves glucose tolerance not only by stimulating insulin secretion, but also by enhancing insulin-independent glucose uptake